Simulations Plus, Inc. (NASDAQ:SLP) Stake Raised by Quantbot Technologies LP

Quantbot Technologies LP grew its holdings in shares of Simulations Plus, Inc. (NASDAQ:SLP) by 191.6% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 5,371 shares of the technology company’s stock after purchasing an additional 3,529 shares during the period. Quantbot Technologies LP’s holdings in Simulations Plus were worth $150,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds also recently made changes to their positions in SLP. Jones Financial Companies Lllp lifted its holdings in shares of Simulations Plus by 53.6% during the fourth quarter. Jones Financial Companies Lllp now owns 1,223 shares of the technology company’s stock valued at $34,000 after purchasing an additional 427 shares during the last quarter. US Bancorp DE lifted its stake in Simulations Plus by 14.3% during the fourth quarter. US Bancorp DE now owns 5,687 shares of the technology company’s stock valued at $159,000 after buying an additional 713 shares in the last quarter. Franklin Resources Inc. boosted its holdings in shares of Simulations Plus by 7.6% in the third quarter. Franklin Resources Inc. now owns 10,797 shares of the technology company’s stock worth $342,000 after buying an additional 766 shares during the period. Cook Wealth LLC increased its position in shares of Simulations Plus by 19.1% in the fourth quarter. Cook Wealth LLC now owns 12,386 shares of the technology company’s stock worth $345,000 after acquiring an additional 1,984 shares in the last quarter. Finally, Principal Financial Group Inc. raised its holdings in shares of Simulations Plus by 2.6% during the third quarter. Principal Financial Group Inc. now owns 87,273 shares of the technology company’s stock valued at $2,794,000 after acquiring an additional 2,226 shares during the period. Institutional investors and hedge funds own 78.08% of the company’s stock.

Insider Activity

In related news, Director Walter S. Woltosz sold 20,000 shares of the firm’s stock in a transaction on Monday, February 3rd. The stock was sold at an average price of $33.91, for a total value of $678,200.00. Following the completion of the transaction, the director now directly owns 3,402,584 shares of the company’s stock, valued at $115,381,623.44. This trade represents a 0.58 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. 19.40% of the stock is owned by company insiders.

Wall Street Analyst Weigh In

A number of brokerages have recently weighed in on SLP. William Blair reiterated an “outperform” rating on shares of Simulations Plus in a report on Wednesday, January 8th. KeyCorp lifted their target price on Simulations Plus from $35.00 to $37.00 and gave the company an “overweight” rating in a research note on Friday, January 24th. One analyst has rated the stock with a sell rating, one has issued a hold rating, five have issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, Simulations Plus presently has an average rating of “Moderate Buy” and a consensus target price of $49.40.

Simulations Plus Trading Up 0.4 %

NASDAQ:SLP opened at $24.29 on Monday. The firm has a market capitalization of $488.03 million, a PE ratio of 60.73 and a beta of 0.89. Simulations Plus, Inc. has a 1 year low of $23.63 and a 1 year high of $51.22. The firm’s fifty day simple moving average is $30.80 and its 200 day simple moving average is $30.53.

Simulations Plus Company Profile

Simulations Plus, Inc develops drug discovery and development software for modeling and simulation, and prediction of molecular properties utilizing artificial intelligence and machine learning based technology worldwide. The company operates through two segments, Software and Services. It offers GastroPlus, which simulates the absorption and drug interaction of compounds administered to humans and animals; and DDDPlus and MembranePlus simulation products.